P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?. (5th April 2022) - Popat, R; Badros, A; Kumar, S; Rodriguez-Otero, P; Cohen, A; Manier, S; Voorhees, P; Gay, F; Rifkin, R; Martin, T; Chari, A; Weisel, K; et al.